Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder - An 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients

Phytomedicine

Volumn 10, Issue SUPPL. 4, 2003, Pages 38-49

  Boerner, R J ^a   Sommer, H ^b   Berger, W ^c   Kuhn, U ^c   Schmidt, U ^c   Mannel, M ^d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Pract for Psychiatry and Neurology   (Germany)

^c IMF Inst Interdis Med Res   (Germany)

^d Lichtwer Pharma AG   (Germany)

Author keywords

Anxiety outcome measures; Buspirone; Clinical trial; Generalized Anxiety Disorder; Kava; Opipramol; Out patient treatment

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BUSPIRONE; IMIPRAMINE; KAVA; LI 150; OPIPRAMOL; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; VENLAFAXINE;

ADULT; ARTICLE; BOERNER ANXIETY SCALE; BRONCHITIS; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; GENERALIZED ANXIETY DISORDER; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHARYNGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; SEDATION; SELF RATING ANXIETY SCALE; SKIN DISEASE; TACHYCARDIA; VOMITING; WITHDRAWAL SYNDROME;

PIPER METHYSTICUM;

EID: 0037911537     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1078/1433-187X-00309     Document Type: Article

References (42)

1. Allgulander C, Hackett D, Salinas E (2001) Venlafaxine extended release (ER) in the treatment of generalized anxiety disorder. Twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 179: 15-22
2. Anonymous (1998) Buspirone HCl. In: Drug facts and comparisons, 1998 edition: 1593-1596. Facts and Comparisons, St. Louis, MO
3. Boerner RJ (2001) Kava kava in the treatment of generalized anxiety disorder, simple phobia and specific social phobia. Phytother Res 15: 646-647
4. Boerner RJ (2002a) Angststörungen. In: Neuro-Psychopharmaka, vol. 3, 2nd ed. (eds Riederer P et.al.). Springer, Wien (in press)
5. Boerner RJ (2002b) The Boerner Anxiety Scale (BOEAS), a new scale for measurement of anxiety symptoms (submitted)
6. Brawman-Mintzer O, Lydiard RB (1996) Generalized anxiety disorder: issues in epidemiology. J Clin Psychiatry 57(suppl 7): 3-8
7. Buckley JP, Furgiuele AR, O'Hara MJ (1967) Pharmacology of Kava - 2. Psychopharmacol Bull 4: 11-12
8. Bullinger M, Kirchberger I, von Steinbüchel N (1993) Der Fragebogen Alltagsleben - ein Verfahren zur Erfassung der gesundheitsbezogenen Lebensqualität. Zeitschrift für Medizinische Psychologie 2: 121-131
9. Bundesinstitut für Arzneimittel und Medizinprodukte (1990) Monographie: Piperis methystici rhizoma (Kava-Kava Wurzelstock). [Federal Office for Medicines and Medicinal Products. Monograph: Kava-Kava]. BAnz 101 (01 Jun 1990)
10. CIBA-GEIGY GmbH (1994) Insidon®. Drug Information Sheet, October 1994
11. Davidson JR, DuPont RL, Hedges D, Haskins JT (1999) Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 60: 528-535
12. Escher M, Desmeules J, Giostra E, Mentha G (2001) Hepatitis associated with Kava, a herbal remedy for anxiety. BMJ 322: 139
13. Fulton B, Brogden RN (1997) Buspirone: an updated review of its clinical pharmacology and therapeutic applications. CNS Drugs 7: 68-88
14. Görtelmeyer R (1985) On the Development of a Standardized Sleep Inventory for the Assessment of Sleep. In: Methods of Sleep Research (eds Kubicki S, Hermann WM): 93-98. Gustav Fischer, Stuttgart
15. Hellwig B (2000) In der Diskussion: Kava-Kava Schädliche Stoffe im Aceton-Extrakt? Dtsch Apoth Ztg 29: 3361
16. Hiller W, Zaudig M, Mombour W, Bronisch T (1993) Routine psychiatric examinations guided by ICD-10 Diagnostic Checklists (International Diagnostic Checklists). Eur Arch Psychiatry Clin Neurosci 242: 218-223
17. Katon W, Von Korff M, Lin E, et al. (1990) Distressed high utilizers of medical care: DSM-III-R diagnoses and treatment needs. Gen Hosp Psychiatry 12: 355-362
18. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51: 8-19
19. Lohse MJ, Mueller-Oerlinghausen B (2001) Psychopharmaka. In: Arzneiverordnungs-Report 2001 (eds Schwabe U, Paffrath D): 597-629. Springer, Berlin, Heidelberg
20. Malsch U, Kieser M (2001) Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. Psychopharmacology (Berl) 157: 277-283
21. Meyer HJ (1962) Pharmakologie der wirksamen Prinzipien des Kawa-Rhizoms (Piper methysticum Forst.). Arch Int Pharmacodyn Ther 88: 505-536
22. Meyer HJ (1967) Pharmacology of Kava - 1. Psychopharmacol Bull 4: 10-11
23. Möller HJ, Volz HP, Reimann IW, Stoll KD (2001) Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolamtreated group. J Clin Psychopharmacol 21: 59-65
24. Montgomery SA (1999) Alternatives to placebo-controlled trials in psychiatry. ECNP Consensus Meeting, September 26, 1996, Amsterdam. European College of Neuropsychopharmacology. Eur Neuropsychopharmacol 9: 265-269
25. Pittler MH, Ernst E (2001) Kava extract for treating anxiety (Cochrane Review). Cochrane Database Syst Rev 4: CD003383
26. Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Iyengar MK (2001) Paroxetine in the treatment of generalized anxiety disorder: Results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 62: 350-357
27. Rickels K, Downing R, Schweizer E, et al. (1993) Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 50: 884-895
28. Rickels K, Pollack MH, Sheehan DV, Haskins JT (2000) Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxienty disorder. Am J Psychiatry 157: 968-974
29. Russmann S, Lauterburg BH, Helbling A (2001) Kava hepatotoxicity. Ann Intern Med 135: 68-69
30. th edition): 78-86. Springer, Berlin, Heidelberg
31. Schweitzer E, Rickels K (1997) Strategies for treatment of generalized anxiety in the primary care setting. J Clin Psychiatry 58(suppl 3): 27-31
32. Shader RJ, Greenblatt DJ (1993) Use of benzodiazepines in anxiety disorders. N Engl J Med 328: 1398-1405
33. Sheehan DV (1999) Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder. J Clin Psychiatry 60(suppl 22): 23-28
34. Singh YN (1992) Kava: An overview. J Ethnopharmacol 37: 13-45
35. Steiner GG (2000) The correlation between cancer incidence and kava consumption. Hawaii Med J 59: 420-422
36. Strahl S, Ehret V, Dahm HH, Maier KP (1998) Nekrotisierende Hepatitis nach Einnahme pflanzlicher Heilmittel. Dtsch Med Wochenschr 123: 1410-1414
37. van Lith ND, Motke JC (1983) Opipramol in the climacteric syndrome. A double-blind, placebo-controlled trial. Maturitas 5: 17-23
38. Volz HP, Möller HJ (1998) Opipramol bei Angst- und Somatisierungsstudien. Fortschr Neurol Psychiat 66 (suppl 1): S21-S24
39. Volz HP, Möller HJ, Reimann I, Stoll KD (2000) Opipramol for the treatment of somatoform disorders, results from a placebo-controlled trial. Eur Neuropsychopharmacol 10: 211-217
40. von Zerssen D (1973) Beschwerdenskalen bei Depressionen. Therapiewoche 46: 4426-4440
41. World Health Organisation (1992) The ICD-10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. WHO, Geneve
42. Yonkers KA, Warshaw MG, Massion AO, Keller MB (1996) Phenomenology and course of generalised anxiety disorder. Br J Psychiatry 168: 308-313